Article | DDR therapeutics
0
Patrys CEO and MD, Dr James Campbell, has written an article titled “DDR therapeutics and synthetic lethality – a precise…
Article | AstraZeneca
AstraZeneca has published an article titled, “Combatting cancer by exploiting the DNA Damage Response.” Read it here.
Newsletter | June 2019
Patrys is pleased to share its latest Newsletter, published June 2019. Key highlights: Letter from our CEO Progress with PAT-DX1…
Bioshares | October 2018
Patrys was featured in the latest issue of BioShares in an article titled, “Patrys Selects Indications for Unique Cancer Treatment…
Media | Biopharma Deal Makers
Biopharma Deal Makers has published an article titled, “Nuclear-penetrating DNA binding antibodies as cancer therapies.” Read it here.
Newsletter | May 2018
Patrys is pleased to share its latest Newsletter, published May 2018. Key highlights: Letter from our CEO Update on deoxymabs…
Media | Stockhead
Stockhead has published an article titled, “Aussie cancer drug developer jumps 400pc after human tissue tests” Read it here.
Newsletter | June 2017
Patrys is pleased to share its latest Newsletter, published June 2017. Key highlights: Letter from our CEO Update on deoxymabs…